Aligos Therapeutics, Inc. ALGS
Aligos Therapeutics, Inc. (Nasdaq: ALGS) is an infectious disease drug developer. Its lead program, Pevifoscorvir sodium (ALG-000184), is in Phase 2 for Chronic hepatitis B virus (HBV) infection. Its next catalyst on record is ALG-170675: MAD cohort initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ALG-170675 — MAD cohort initiation (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Pevifoscorvir sodium (ALG-000184) | Chronic hepatitis B virus infection | small molecule | Phase 2 |
| ALG-055009 | Metabolic dysfunction-associated steatohepatitis (MASH) and obesity | small molecule | Phase 2 |
| ALG-170675 | Chronic hepatitis B virus infection | oligonucleotide-other | Phase 1 |
Recent results and decisions
- Nov 6, 2026started Partner Amoytop advanced ALG-170675 into Phase 1 clinical studies in China.
Our partner Amoytop advanced ALG-170675 into Phase 1 clinical studies.
Filing - Apr 14, 2026n/a First interim analysis: DSMB recommended continuing and raising HBeAg- cohort (Part 2a) from 74 to 100 participants; futility criteria not met; well tolerated; no efficacy data disclosed.
A futility analysis was performed; the prespecified futility criteria was not met, per the statistical analysis plan.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.